In core-binding factor (CBF) AML, adding gemtuzumab ozogamicin (CD33-targeted monoclonal antibody conjugated to the calicheamicin payload) to high-dose cytarabine-based chemotherapy increased the long-term survival rate from 50% to 75+%13–17. The gene discussed is CD33; the disease is acute myeloid leukemia.